Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | GCK | P35557 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664271 | 0.88 | PTGS2 (0.46) | SMN1; SMN2ALDH1A1HTTTDP1L3MBTL1 | |
| SCHEMBL2664245 | 0.88 | ENPP2 (0.48) | SMN1; SMN2ALDH1A1HTTTDP1L3MBTL1 | |
| SCHEMBL13814624 | 0.86 | HTT (0.63) | SMN1; SMN2ALDH1A1HTTTDP1L3MBTL1 | |
| SCHEMBL2758531 | 0.86 | HTT (0.63) | SMN1; SMN2ALDH1A1HTTTDP1L3MBTL1 | |
| SCHEMBL11547843 | 0.85 | HTT (0.58) | SMN1; SMN2ALDH1A1HTTPTGS1PTGS2 | |
| SCHEMBL2664281 | 0.84 | PTGS2 (0.49) | SMN1; SMN2ALDH1A1HTTTDP1L3MBTL1 | |
| SCHEMBL2668246 | 0.83 | MEN1 (0.50) | SMN1; SMN2ALDH1A1HTTPTGS2GCK | |
| SCHEMBL2664231 | 0.83 | GCK (0.58) | GCK | |
| SCHEMBL17207939 | 0.82 | HTT (0.67) | SMN1; SMN2ALDH1A1HTTTDP1L3MBTL1 | |
| SCHEMBL17207945 | 0.82 | HTT (0.67) | SMN1; SMN2ALDH1A1HTTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812048-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090030046-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030046-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, HK1 | SMN1; SMN2 3742/4885ALDH1A1 2844/4885HTT 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.